FibroGen, Inc. (FGEN)
| Market Cap | 3.25B |
| Revenue (ttm) | 176.32M |
| Net Income (ttm) | -189.29M |
| Shares Out | 89.85M |
| EPS (ttm) | -2.11 |
| PE Ratio | n/a |
| Forward PE | 80.65 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | March 5 |
| Last Price | $33.59 |
| Previous Close | $33.73 |
| Change ($) | -0.14 |
| Change (%) | -0.42% |
| Day's Open | 33.70 |
| Day's Range | 33.31 - 34.50 |
| Day's Volume | 327,440 |
| 52-Week Range | 22.65 - 57.21 |
FibroGen suffered a setback after U.S. regulators requested an additional meeting before reviewing the company's anemia treatment. In response, FGEN stock crashed on Tuesday.
FibroGen (FGEN) delivered earnings and revenue surprises of -120.69% and -25.01%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
SAN FRANCISCO, March 01, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (Nasdaq: FGEN) and its partner, AstraZeneca (LSE/STO/Nasdaq: AZN), today announced that the Cardiovascular and Renal Drugs Advi...
• Strong Fourth Quarter China Roxadustat Net Sales of $29.2 Million and 2020 full-year Net Sales of $72.5 Million
FibroGen (FGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SAN FRANCISCO, Feb. 18, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its fourth quarter and full year 2020 financial results on Monday, March 1 after the market close. ...
SAN FRANCISCO, Feb. 12, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in fireside chats at the followi...
FibroGen, Inc. is a commercial-stage global biopharmaceutical company developing and commercializing innovative therapeutics treating anemia, fibrotic diseases, and cancer. FibroGen's pipeline...
SAN FRANCISCO, Dec. 22, 2020 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced dosing of the first patient in the ZEPHYRUS-2 Phase 3 clinical study of pamrevlumab in patients w...
SAN FRANCISCO, Dec. 18, 2020 (GLOBE NEWSWIRE) -- FibroGen, Inc. (Nasdaq: FGEN) today announced that the U.S. Food and Drug Administration (FDA) has extended the review period of the New Drug A...
New data show safety and efficacy of roxadustat in treating anemia secondary to lower-risk myelodysplastic syndrome s (MDS) regardless of ring sideroblast (RS) or baseline e rythro poietin level
FibroGen's (FGEN) Evrenzo (roxadustat) wins second approval in Japan for treating anemia caused by chronic kidney disease in non-dialysis-dependent patients.
Approval by MHLW provides new HIF-PH inhibitor treatment option for healthcare providers and adult patients with anemia of CKD not on dialysis Approval by MHLW provides new HIF-PH inhibitor tr...
FibroGen, Inc. (FGEN) CEO Enrique Conterno on Q3 2020 Results - Earnings Call Transcript
SAN FRANCISCO, Nov. 06, 2020 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in fireside chats at the followi...
FibroGen (FGEN) delivered earnings and revenue surprises of 139.33% and -10.19%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
- Strong T hird Quarter China Roxadustat Net Sales of $22.7 M illion - - Conference Call Today at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time -
SAN FRANCISCO, Oct. 29, 2020 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its third quarter 2020 financial results on Thursday, November 5 after the market close. FibroGen w...
In non-dialysis and dialysis-dependent CKD patients, Major Adverse Cardiovascular Event (MACE) and MACE+ incidence rates were lowest when patients achieved hemoglobin levels ≥ 1 0 g/dL
Late-breaking abstracts explore cardiovascular outcomes of patients with anemia in chronic kidney disease ( CKD ) treated with roxadustat, including associations with achieved hemoglobin level...
A drug from San Francisco-based FibroGen Inc. (NASDAQ:FGEN) is one of five medications the Food and Drug Administration is expected to rule on in the next three months in what BioPharma Dive c...
SAN FRANCISCO, Sept. 08, 2020 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) announced the appointment of Percy Carter, MBA, PhD, to the newly-created position of Chief Scientific Officer...
SAN FRANCISCO, Aug. 11, 2020 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) announced the initiation of LELANTOS, a Phase 3, randomized, double-blind, placebo-controlled trial of pamrevlu...
FibroGen's (FGEN) CEO Enrique Conterno on Q2 2020 Results - Earnings Call Transcript
FibroGen (FGEN) delivered earnings and revenue surprises of -61.02% and 22.22%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
- Strong Second Quarter China Roxadustat Net Sales of $15.7 million - - Conference Call Today at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time -
- Appoints Aoife Brennan, M.B., B.Ch., President and CEO of Synlogic Inc. (NASDAQ:SYBX) -- Appoints Ben Cravatt, Ph.D., Professor and the Norton B. Gilula Chair of Chemical Biology in the Depa...
FibroGen (FGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Have you missed the rally of these 4 stocks in the past three years? HubSpot, Everbridge, FibroGen, and Inphi Corporation have grown more than 100% since the beginning of 2017 despite posting ...
SAN FRANCISCO, July 23, 2020 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its second quarter 2020 financial results on Thursday, August 6 after the market close. FibroGen ...
FibroGen (FGEN) enrolls the first patient in a placebo-controlled phase II study on pamrevlumab in hospitalized patients with acute COVID-19 infection in the United States.
SAN FRANCISCO, June 23, 2020 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced the initiation of a randomized, double-blind, placebo-controlled Phase 2 Study investigating th...
SAN FRANCISCO, June 22, 2020 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) announced the appointment of Thane Wettig to the newly-created position of Chief Commercial Officer, where he w...
FibroGen (FGEN) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
FibroGen (FGEN) starts a phase II/III study in Italy on pamrevlumab versus standard of care in patients with severe COVID-19 infection.
SAN FRANCISCO, June 08, 2020 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) announced data from three roxadustat clinical trials, including the Phase 3 DOLOMITES study evaluating roxadusta...
Additional Pamrevlumab Clinical Trials Planned in Patients Hospitalized in United States with Severe COVID-19 Additional Pamrevlumab Clinical Trials Planned in Patients Hospitalized in United ...
Submission for the treatment of anemia in adult patients with chronic kidney disease Submission for the treatment of anemia in adult patients with chronic kidney disease
FibroGen, Inc. (FGEN) CEO Enrique Conterno on Q1 2020 Results - Earnings Call Transcript
SAN FRANCISCO, May 08, 2020 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will participate in the Bank of America Securities 2020 Health Care Conference that is being held virtually on M...
FibroGen (FGEN) delivered earnings and revenue surprises of -196.67% and -64.10%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
FibroGen (FGEN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
FibroGen (FGEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SAN FRANCISCO, April 20, 2020 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the United Kingdom’s High Court of Justice has held certain patents1 relating to methods ...
FibroGen, Inc. (FGEN) CEO Enrique Conterno on Q4 2019 Results - Earnings Call Transcript
FibroGen (FGEN) delivered earnings and revenue surprises of -80.65% and -74.01%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
FibroGen (FGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The FDA accepts FibroGen's (FGEN) NDA for roxadustat for the treatment of anemia of chronic kidney disease in both non-dialysis-dependent and dialysis-dependent patients.
About FGEN
FibroGen, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases that is in Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States and Europe; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. The company is also developing Pamrevlumab, a human monoclonal antibody that inhibits ... [Read more...]
| Industry Biotechnology | IPO Date Nov 14, 2014 |
| CEO Enrique Conterno | Employees 531 |
| Stock Exchange NASDAQ | Ticker Symbol FGEN |
Financial Performance
In 2020, FibroGen's revenue was $176.32 million, a decrease of -31.28% compared to the previous year's $256.58 million. Losses were -$189.29 million, 145.9% more than in 2019.
Analyst Forecasts
According to 10 analysts, the average rating for FibroGen stock is "Buy." The 12-month stock price forecast is 54.56, which is an increase of 62.43% from the latest price.